Skip to content

AbbVie

NYSE: ABBV · USD

AbbVie revenue90

Quarterly and annual revenue from company filings.

Business drivers

Business lines and operating measures.

SKYRIZI · Immunology revenue

Reported quarterly SKYRIZI · Immunology revenue. Quarterly figures · USD

SKYRIZI · Immunology revenue. Reported quarterly SKYRIZI · Immunology revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 20265,505,000,000Filed Aug 3, 2026
Mar 31, 2026From Jan 1, 20264,483,000,000Filed May 8, 2026
Jun 30, 2025From Apr 1, 20254,423,000,000Filed Aug 3, 2026
Mar 31, 2025From Jan 1, 20253,425,000,000Filed May 8, 2026

RINVOQ · Immunology revenue

Reported quarterly RINVOQ · Immunology revenue. Quarterly figures · USD

RINVOQ · Immunology revenue. Reported quarterly RINVOQ · Immunology revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 20262,525,000,000Filed Aug 3, 2026
Mar 31, 2026From Jan 1, 20262,119,000,000Filed May 8, 2026
Jun 30, 2025From Apr 1, 20252,028,000,000Filed Aug 3, 2026
Mar 31, 2025From Jan 1, 20251,718,000,000Filed May 8, 2026

Botox Therapeutic · Neuroscience revenue

Reported quarterly Botox Therapeutic · Neuroscience revenue. Quarterly figures · USD

Botox Therapeutic · Neuroscience revenue. Reported quarterly Botox Therapeutic · Neuroscience revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 30, 2026From Apr 1, 20261,042,000,000Filed Aug 3, 2026
Mar 31, 2026From Jan 1, 20261,009,000,000Filed May 8, 2026
Jun 30, 2025From Apr 1, 2025928,000,000Filed Aug 3, 2026
Mar 31, 2025From Jan 1, 2025866,000,000Filed May 8, 2026

Independent series; they may overlap and do not form an additive breakdown.

  • The supplied observations provide limited history and no operating-volume measures.

Products & projects

RC148 (ABBV-1480)

(RemeGen). Under the terms of the agreement, AbbVie received an exclusive global license excluding China to develop, manufacture and commercialize RC148 (ABBV-1480), a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody in development for the treatment of multiple advanced solid tumors.

Filed · source for RC148 (ABBV-1480)

Revenue history

USD millions · Fiscal periods
Mar 31, 2013 through Jun 30, 2026

Quarterly data

AbbVie quarterly financial data in USD millions. FY denotes the company's fiscal year. YTD covers reported quarters only.
Fiscal quarterEndedTotal revenueUSD millions
FY 2026 Q2Jun 30, 202616,990, +13.3% versus FY 2026 Q1
FY 2026 Q1Mar 31, 202615,002, −9.7% versus FY 2025 Q4
FY 2025 Q4Dec 31, 202516,618, +5.3% versus FY 2025 Q3
FY 2025 Q3Sep 30, 202515,776, +2.3% versus FY 2025 Q2
FY 2025 Q2Jun 30, 202515,423, +15.6% versus FY 2025 Q1
FY 2025 Q1Mar 31, 202513,343, −11.6% versus FY 2024 Q4
FY 2024 Q4Dec 31, 202415,102, +4.4% versus FY 2024 Q3
FY 2024 Q3Sep 30, 202414,460, 0.0% versus FY 2024 Q2
FY 2024 Q2Jun 30, 202414,462, +17.5% versus FY 2024 Q1
FY 2024 Q1Mar 31, 202412,310, −13.9% versus FY 2023 Q4
FY 2023 Q4Dec 31, 202314,301, +2.7% versus FY 2023 Q3
FY 2023 Q3Sep 30, 202313,927, +0.4% versus FY 2023 Q2
FY 2023 Q2Jun 30, 202313,865, +13.4% versus FY 2023 Q1
FY 2023 Q1Mar 31, 202312,225, −19.2% versus FY 2022 Q4
FY 2022 Q4Dec 31, 202215,121, +2.1% versus FY 2022 Q3
FY 2022 Q3Sep 30, 202214,812, +1.6% versus FY 2022 Q2
FY 2022 Q2Jun 30, 202214,583, +7.7% versus FY 2022 Q1
FY 2022 Q1Mar 31, 202213,538, −9.1% versus FY 2021 Q4
FY 2021 Q4Dec 31, 202114,886, +3.8% versus FY 2021 Q3
FY 2021 Q3Sep 30, 202114,342, +2.7% versus FY 2021 Q2
FY 2021 Q2Jun 30, 202113,959, +7.3% versus FY 2021 Q1
FY 2021 Q1Mar 31, 202113,010, −6.1% versus FY 2020 Q4
FY 2020 Q4Dec 31, 202013,858, +7.4% versus FY 2020 Q3
FY 2020 Q3Sep 30, 202012,902, +23.8% versus FY 2020 Q2
FY 2020 Q2Jun 30, 202010,425, +21.0% versus FY 2020 Q1
FY 2020 Q1Mar 31, 20208,619, −1.0% versus FY 2019 Q4
FY 2019 Q4Dec 31, 20198,704, +2.7% versus FY 2019 Q3
FY 2019 Q3Sep 30, 20198,479, +2.7% versus FY 2019 Q2
FY 2019 Q2Jun 30, 20198,255, +5.5% versus FY 2019 Q1
FY 2019 Q1Mar 31, 20197,828, −5.7% versus FY 2018 Q4
FY 2018 Q4Dec 31, 20188,305, +0.8% versus FY 2018 Q3
FY 2018 Q3Sep 30, 20188,236, −0.5% versus FY 2018 Q2
FY 2018 Q2Jun 30, 20188,278, +4.3% versus FY 2018 Q1
FY 2018 Q1Mar 31, 20187,934, +2.5% versus FY 2017 Q4
FY 2017 Q4Dec 31, 20177,739, +10.6% versus FY 2017 Q3
FY 2017 Q3Sep 30, 20176,995, +0.7% versus FY 2017 Q2
FY 2017 Q2Jun 30, 20176,944, +6.2% versus FY 2017 Q1
FY 2017 Q1Mar 31, 20176,538, −3.8% versus FY 2016 Q4
FY 2016 Q4Dec 31, 20166,796, +5.7% versus FY 2016 Q3
FY 2016 Q3Sep 30, 20166,432, −0.3% versus FY 2016 Q2
FY 2016 Q2Jun 30, 20166,452, +8.3% versus FY 2016 Q1
FY 2016 Q1Mar 31, 20165,958, −6.9% versus FY 2015 Q4
FY 2015 Q4Dec 31, 20156,400, +7.7% versus FY 2015 Q3
FY 2015 Q3Sep 30, 20155,944, +8.6% versus FY 2015 Q2
FY 2015 Q2Jun 30, 20155,475, +8.6% versus FY 2015 Q1
FY 2015 Q1Mar 31, 20155,040, −7.6% versus FY 2014 Q4
FY 2014 Q4Dec 31, 20145,452, +8.6% versus FY 2014 Q3
FY 2014 Q3Sep 30, 20145,019, +1.9% versus FY 2014 Q2
FY 2014 Q2Jun 30, 20144,926, +8.0% versus FY 2014 Q1
FY 2014 Q1Mar 31, 20144,563, −10.7% versus FY 2013 Q4
FY 2013 Q4Dec 31, 20135,111, +9.7% versus FY 2013 Q3
FY 2013 Q3Sep 30, 20134,658, −0.7% versus FY 2013 Q2
FY 2013 Q2Jun 30, 20134,692, +8.4% versus FY 2013 Q1
FY 2013 Q1Mar 31, 20134,329, Change unavailable versus FY 2012 Q4
Sources and definitions

Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.

Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.

Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.

Total revenue
Reported consolidated revenue as tagged in the SEC filing, including all company businesses.